Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK of SB26 in Healthy Volunteers
NCT03630627Phase 1Completed
- Sponsor
- Samsung Bioepis
- Start
- Aug 2018
- Primary completion
- Apr 2020
- Modality
- Antibody Fragments, Peptides, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SB26 in acute pancreatitis (AP), sponsored by Samsung Bioepis. Primary endpoints: Incidence of Treatment-Emergent Adverse Events, Incidence of Adverse Events leading to discontinuation and 4 more. Started Aug 2018; status: completed.
02
Drugs
SB26
03
Conditions
acute pancreatitis (AP)
Beyond the preview
Go deeper on NCT03630627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03630627.